The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Harvard University launched LabXchange in January and the free science education platform acquired new resonance during the COVID-19 lockdowns that saw millions of students around the world move ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...

Amgen was founded in 1980 and today employs more than 27,000 ... “What happened almost 20 years ago, the town council and ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

The latest trading session saw Amgen (AMGN) ending at $267.10, denoting a -1.14% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.12% for the ...